Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma

Trial Details

NCT ID

NCT06854445

Phase

PHASE2

Sponsor

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection

Locations (sample)

• Wuhu, Anhui, China|31.35259,118.42947
• Xiamen, Fujian, China|24.47979,118.08187
• Lanzhou, Gansu, China|36.05701,103.83987
• Guangzhou, Guangdong, China|23.11667,113.25
• Nanning, Guangxi, China|22.81667,108.31667

Key Eligibility Criteria

• The subjects voluntarily participate in this study, sign the informed consent form, and have good compliance;
• Age ≥18 years (calculated from the date of informed consent);
• Eastern Cooperative Oncology Group (ECOG) score 0 \~ 2 points;
• Expected survival greater than 12 weeks;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.